-
Top Stories: Calithera Biosciences (NASDAQ:CALA), Protalix BioTherapeutics (NYSEMKT:PLX), KaloBios Pharmaceuticals (NASDAQ:KBIO), Keryx Biopharmaceuticals Inc. (NASDAQ:KERX), TetraLogic Pharmaceuticals Corporation (NASDAQ:TLOG)
On Thursday shares of Calithera Biosciences, Inc. (NASDAQ:CALA) closed at $12.14. Company’s EPS growth for next 5 years is recorded as 75.00%.Calithera Biosciences, Inc. (NASDAQ:CALA) announced its participated at the Bank of America Merrill Lynch 2015 Healthcare Conference, on Tuesday, May 12, 2015 at 8:00 a.m. Pacific Time at The Encore at Wynn Hotel in…
-
Active Watch List: Keryx Biopharmaceuticals Inc. (NASDAQ:KERX), Petroleo Brasileiro Petrobras SA (ADR) (NYSE:PBR), Transition Therapeutics Inc. (NASDAQ:TTHI), Lowe’s Companies (NYSE:LOW), Comcast (NASDAQ:CMCSA)
On Monday shares of Keryx Biopharmaceuticals Inc. (NASDAQ:KERX) closed at $10.70. Company’s sales growth for last 5 years was -15.60%. JPMorgan Chase & Co. reissued their overweight rating on shares of Keryx Biopharmaceuticals (NASDAQ:KERX) in a research report sent to investors on Saturday morning. Petroleo Brasileiro Petrobras SA (ADR) (NYSE:PBR) in last trading activity decreased…
-
Morning Alert: Cytokinetics, Incorporated (NASDAQ:CYTK), Keryx Biopharmaceuticals Inc. (NASDAQ:KERX), HEICO Corporation (NYSE:HEI), Hudson Global, Inc (NASDAQ:HSON), White Mountains Insurance Group, (NYSE:WTM)
On Monday shares of Cytokinetics, Incorporated (NASDAQ:CYTK) closed at $6.65. Company’s sales growth for last 5 years was -10.50% and EPS growth for next 5 years is recorded as 15.00%. Zacks downgraded shares of Cytokinetics, Inc. (NASDAQ:CYTK) from a buy rating to a hold rating. Keryx Biopharmaceuticals Inc. (NASDAQ:KERX) in last trading activity increased 14.81%…
-
Today’s Hot List: Keryx Biopharmaceuticals Inc. (NASDAQ:KERX), Cytokinetics, Incorporated (NASDAQ:CYTK), Marlin Midstream Partners (NASDAQ:FISH), Samson Oil & Gas (NYSEMKT:SSN), Tenet Healthcare (NYSE:THC)
On Thursday shares of Keryx Biopharmaceuticals Inc. (NASDAQ:KERX) closed at $10.66. Company’s sales growth for last 5 years was -15.60%. Keryx Biopharmaceuticals Inc. (NASDAQ:KERX) announced the completion of the previously announced transition of the CEO role from Ron Bentsur to Greg Madison. Cytokinetics, Incorporated (NASDAQ:CYTK) in last trading activity moved down -6.12% to close at…
-
Worth Watching Stocks: JD.com (NASDAQ:JD), Keryx Biopharmaceuticals Inc. (NASDAQ:KERX), L-3 Communications Holdings Inc. (NYSE:LLL), Freescale Semiconductor, (NYSE:FSL), Knowles Corporation (NYSE:KN)
On Friday shares of JD.com, Inc. (NASDAQ:JD) closed at $34.72. Company’s sales growth for last 5 years was 108.50% and EPS growth for next 5 years is recorded as 30.51%. Equities researchers at Jefferies Group lifted their price target on shares of JD.Com (NYSE:JD) from $38.00 to $43.00 in a research report issued on Friday.…
-
Shining on Major News: Keryx Biopharmaceuticals Inc. (NASDAQ:KERX), Carver Bancorp (NASDAQ:CARV), PH Glatfelter (NYSE:GLT), California Water Service (NYSE:CWT), Main Street Capital (NYSE:MAIN)
On Mar 10, Keryx Biopharmaceuticals Inc. (NASDAQ:KERX) announced the appointment of Mr. Greg Madison, the Company’s President and Chief Operating Officer and incoming Chief Executive Officer, to its Board of Directors, effective March 10, 2015. With the addition of Mr. Madison to Keryx’s Board, the Company has increased the size of its Board to 8…
-
Watch 5 Stocks: Corning Inc. (NYSE:GLW), Keryx Biopharmaceuticals Inc. (NASDAQ:KERX), Fifth Street Finance Corp. (NASDAQ:FSC), BlackBerry Ltd (NASDAQ:BBRY), The Dow Chemical (NYSE:DOW)
Corning Inc. (NYSE:GLW) announced last week that Gionee Communication Equipment Co. Ltd has chosen Corning’s Gorilla Glass 3 with NDR for both the front and back glass panels of its newly announced Ultra Smartphone Elife S7. On Tuesday shares of Corning Inc. (NYSE:GLW) closed at $23.05. Company’s sales growth for last 5 years was 12.50%…
-
Notable Moves: Keryx Biopharmaceuticals Inc. (NASDAQ:KERX), Google Inc (NASDAQ:GOOGL), Ardelyx (NASDAQ:ARDX), Tyson Foods (NYSE:TSN), Canadian National Railway Company (NYSE:CNI)
Maxim Group analyst Jason Kolbert reiterated a Buy rating and $32 price target on Keryx Biopharmaceuticals (NASDAQ: KERX) after new publications on Auryxia supports its use and cost effectiveness. On Monday shares of Keryx Biopharmaceuticals Inc. (NASDAQ:KERX) closed at $12.62. Company’s sales growth for last 5 years was -15.60%. Google Inc (NASDAQ:GOOGL) prepares algorithm change;…
-
Stock in News: Keryx Biopharmaceuticals Inc. (NASDAQ:KERX), Puma Biotechnology (NYSE:PBYI), MBIA Inc. (NYSE:MBI), Ericsson (NASDAQ:ERIC), Peoples Bancorp Inc. (NASDAQ:PEBO)
On 2 March 2015, Keryx Biopharmaceuticals Inc. (NASDAQ:KERX) reported a loss of 44 cents per share in the fourth quarter of 2014, much wider than both the Zacks Consensus Estimate of a loss of 38 cents and the year-ago quarter figure of 21 cents. On Thursday shares of Keryx Biopharmaceuticals Inc. (NASDAQ:KERX) closed at $13.19.…
-
Keep Eyes on: JPMorgan Chase & Co. (NYSE:JPM), Keryx Biopharmaceuticals Inc. (NASDAQ:KERX), Frontline (NYSE:FRO), Terreno Realty Corp. (NYSE:TRNO), Verizon Communications (NYSE:VZ)
On February 5, The Urban Institute and JPMorgan Chase & Co. (NYSE:JPM) said that they have launched a multi-year program that aims to inform and assess the impact of JPMorgan Chase’s key philanthropic initiatives. On Monday shares of JPMorgan Chase & Co. (NYSE:JPM) closed at $57.82. Company’s sales growth for last 5 years was -4.90%…